Incyte Corp (INCY.OQ)
13 Aug 2018
The U.S. Food and Drug Administration on Friday approved the lower dose of a rheumatoid arthritis drug developed by Eli Lilly and Incyte Corp, but declined to approve its higher and more lucrative dose.
June 1 The U.S. Food and Drug Administration on Friday approved the lower dose of a rheumatoid arthritis drug developed by Eli Lilly and Incyte Corp, but declined to approve its higher and more lucrative dose.
* INCYTE REPORTS 2018 FIRST-QUARTER FINANCIAL RESULTS AND UPDATES ON KEY CLINICAL PROGRAMS
An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.
* IMMUNOVACCINE AND INCYTE EXPAND CLINICAL COLLABORATION EVALUATING COMBINATION IMMUNOTHERAPIES IN ADVANCED RECURRENT OVARIAN CANCER
* Approval in only 2 mg dose limits commercial potential- analysts
April 23 A U.S. FDA advisory committee voted 10-to-5 on Monday against approving a higher dose of a rheumatoid arthritis drug developed by Eli Lilly & Co and Incyte Corp, but recommended that it be approved in a lower dose.
An experimental rheumatoid arthritis drug developed by Eli Lilly and Co and Incyte Corp poses serious risks of deadly blood clots at higher doses, U.S. Food and Drug Administration staff said on Thursday, the latest setback to a treatment regulators declined to approve last year.
April 6 Incyte Corp's shares sank more than 20 percent on Friday after its experimental cancer drug failed to bolster the effectiveness of Merck & Co's blockbuster Keytruda to treat skin cancer patients.
Incyte Corp said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with Merck & Co's Keytruda failed to meet the main goal in a late-stage study.